Significance of neurodegeneration and neuroplasticity serum biomarkers in Parkinson’s disease patients treated with subthalamic stimulation

The ability of serum biomarkers to predict the prognosis and response to deep-brain stimulation (DBS) therapy in Parkinson's disease (PD) patients is promising. Here, we showed that NfL differed between healthy individuals and PD patients and that changes in NfL, GFAP, and BDNF occurred only transiently after DBS surgery. Therefore, subthalamic stimulation does not promote neurodegeneration, and these biomarkers do not serve as clinical improvement endpoints in PD DBS patients.

Authors

Institutions

Publication Details

Journal
npj Parkinson s Disease
Published
2024-10-24
DOI
https://doi.org/10.1038/s41531-024-00808-w
Citations
2
Primary Topic
Neurological disorders and treatments
Type
article
Field-Weighted Citation Impact
0.74

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Significance of neurodegeneration and neuroplasticity serum biomarkers in Parkinson’s disease patients treated with subthalamic stimulation

Fátima Cano-Cano, Francisco Escamilla‐Sevilla, Elena Lozano-Soto, Florencia Sanmartino et al.
2 citations
npj Parkinson s Disease
Neurological disorders and treatments
0.74
article

Significance of neurodegeneration and neuroplasticity serum biomarkers in Parkinson’s disease patients treated with subthalamic stimulation

Fátima Cano-Cano, Francisco Escamilla‐Sevilla, Elena Lozano-Soto, Florencia Sanmartino, Jesús Riqué-Dormido, Raúl Rashid-López, Álvaro Javier Cruz-Gómez, Javier J. González-Rosa, Raúl Espinosa‐Rosso, F. Luis Sánchez-Fernández, Paloma Macías-García, Laura Gómez-Jaramillo, Fernando López-Sosa
article en
2 citations

Abstract

The ability of serum biomarkers to predict the prognosis and response to deep-brain stimulation (DBS) therapy in Parkinson's disease (PD) patients is promising. Here, we showed that NfL differed between healthy individuals and PD patients and that changes in NfL, GFAP, and BDNF occurred only transiently after DBS surgery. Therefore, subthalamic stimulation does not promote neurodegeneration, and these biomarkers do not serve as clinical improvement endpoints in PD DBS patients.

npj Parkinson s DiseaseVol. 10(1)
Universidad de Cádiz (ES), Instituto de Investigación Biosanitaria de Granada (ES), Biomedical Research and Innovation Institute of Cadiz (ES), Hospital Universitario Puerta del Mar (ES)
Ministerio de Ciencia, Innovación y Universidades, Universidad de Cádiz, European Regional Development Fund, Agencia Estatal de Investigación
Zero hunger
Openalex Percentile: Top 26%
Neurological disorders and treatments
0.74
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Significance of neurodegeneration and neuroplasticity serum biomarkers in Parkinson’s disease patients treated with subthalamic stimulation — Fátima Cano-Cano, Francisco Escamilla‐Sevilla, et al. · npj Parkinson s Disease (2024) | TGRS Research Map | TGRS